RU2013115182A - METHOD FOR PREDICING RISK OF DEVELOPMENT OF SEVERE POST-HYPOXIC MYOCARDIAL DAMAGE IN NEWBORNS WITH DIFFERENT PURPOSES OF GESTATION IN THE NEONATAL PERIOD - Google Patents
METHOD FOR PREDICING RISK OF DEVELOPMENT OF SEVERE POST-HYPOXIC MYOCARDIAL DAMAGE IN NEWBORNS WITH DIFFERENT PURPOSES OF GESTATION IN THE NEONATAL PERIOD Download PDFInfo
- Publication number
- RU2013115182A RU2013115182A RU2013115182/15A RU2013115182A RU2013115182A RU 2013115182 A RU2013115182 A RU 2013115182A RU 2013115182/15 A RU2013115182/15 A RU 2013115182/15A RU 2013115182 A RU2013115182 A RU 2013115182A RU 2013115182 A RU2013115182 A RU 2013115182A
- Authority
- RU
- Russia
- Prior art keywords
- content
- risk
- myocardial damage
- serum
- newborns
- Prior art date
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Способ прогнозирования риска развития тяжелого постгипоксического поражения миокарда у новорожденных детей в неонатальном периоде, характеризующийся тем, что проводят исследования биохимических показателей крови пациента, определяют в сыворотке крови содержание васкулоэндотелиального фактора роста VEGF, содержание креатинфосфокиназы KFK, содержание сердечного тропонина TRP и рассчитывают величину оценки рисков Р по формуле:Р=1/(1+e-Y), гдеР - оценка развития рисков, значение Р≥0,5 означает высокие риски;е - основание натуральных логарифмов 2,718…;Y - стандартное уравнение регрессииY=0,72DVEGF+0,65DTRP+0,3DKFK-1,43, гдеDVEGF=RVEGF/NVEGF;DTRP=RTRP/NTRP;DKFK=RKFK/NKFK;VEGF - содержание васкулоэндотелиального фактора роста в сыворотке крови;KFK - содержание креатинфосфокиназы в сыворотке крови,TRP - содержание сердечного тропонина в сыворотке крови,при Р более либо равном 0,5 прогнозируют высокий, а при Р менее 0,5 прогнозируют низкий риск развития тяжелого постгипоксического поражения миокарда.A method for predicting the risk of developing severe posthypoxic myocardial damage in newborns in the neonatal period, characterized in that studies of the patient's biochemical blood parameters are carried out, the content of vasculoendothelial growth factor VEGF, the content of KFK creatine phosphokinase, the content of cardiac troponin TRP are determined and the risk assessment value P is calculated according to the formula: P = 1 / (1 + eY), where P is the assessment of the development of risks, the value of P≥0.5 means high risks; e is the basis of natural logarithms 2, 718 ...; Y is the standard regression equation Y = 0.72DVEGF + 0.65DTRP + 0.3DKFK-1.43, where DVEGF = RVEGF / NVEGF; DTRP = RTRP / NTRP; DKFK = RKFK / NKFK; VEGF is the content of vasculoendothelial growth factor in serum; KFK - serum creatine phosphokinase content, TRP - serum cardiac troponin content, with P greater than or equal to 0.5, high is predicted, and with P less than 0.5, a low risk of developing severe posthypoxic myocardial damage is predicted.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013115182/15A RU2013115182A (en) | 2013-04-04 | 2013-04-04 | METHOD FOR PREDICING RISK OF DEVELOPMENT OF SEVERE POST-HYPOXIC MYOCARDIAL DAMAGE IN NEWBORNS WITH DIFFERENT PURPOSES OF GESTATION IN THE NEONATAL PERIOD |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013115182/15A RU2013115182A (en) | 2013-04-04 | 2013-04-04 | METHOD FOR PREDICING RISK OF DEVELOPMENT OF SEVERE POST-HYPOXIC MYOCARDIAL DAMAGE IN NEWBORNS WITH DIFFERENT PURPOSES OF GESTATION IN THE NEONATAL PERIOD |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2013115182A true RU2013115182A (en) | 2014-10-10 |
Family
ID=53379865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013115182/15A RU2013115182A (en) | 2013-04-04 | 2013-04-04 | METHOD FOR PREDICING RISK OF DEVELOPMENT OF SEVERE POST-HYPOXIC MYOCARDIAL DAMAGE IN NEWBORNS WITH DIFFERENT PURPOSES OF GESTATION IN THE NEONATAL PERIOD |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2013115182A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2747737C1 (en) * | 2020-07-06 | 2021-05-13 | Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации | Method for morphological diagnosis of gestational myocardial maturity in premature infants born at 22-27 weeks gestation |
-
2013
- 2013-04-04 RU RU2013115182/15A patent/RU2013115182A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2747737C1 (en) * | 2020-07-06 | 2021-05-13 | Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации | Method for morphological diagnosis of gestational myocardial maturity in premature infants born at 22-27 weeks gestation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2569921A (en) | Bisymmetric comparison of sub-epidermal moisture values | |
EA201790377A1 (en) | ANTIBODIES TO GLUCAGON AND THEIR APPLICATIONS | |
EA201690421A1 (en) | POSITIVE EFFECT IN THE FORM OF INCREASING THE DURATION OF LIFE IN PATIENTS WITH SALTED TUMORS WITH INCREASED C-REACTIVE PROTEIN LEVELS | |
EA201590247A1 (en) | ANTIBODIES TO SIGLEC-15 | |
CY1124191T1 (en) | TREATMENT OF GRAFV-VERSARY-HOST DISEASE IN TRANSPLANT PATIENTS | |
AR098950A1 (en) | ANTIBODY AGAINST BDCA-2 HUMAN | |
NZ711543A (en) | Anti-cd83 antibodies and use thereof | |
EA201692126A1 (en) | METHOD OF ACHIEVEMENT OF MEDIUM-FREE REMISSION IN SUBJECTS WITH EARLY RHEUMATOID ARTRITIS (RA, RA) | |
WO2014179737A3 (en) | Assays and methods of treatment relating to vitamin d insufficiency | |
AR092423A1 (en) | METHOD OF DIAGNOSIS AND TREATMENT OF CANCER DIRECTED TO MOLECULES EXPRESSED IN CANCEROSA MOTHER CELLS | |
RU2013115182A (en) | METHOD FOR PREDICING RISK OF DEVELOPMENT OF SEVERE POST-HYPOXIC MYOCARDIAL DAMAGE IN NEWBORNS WITH DIFFERENT PURPOSES OF GESTATION IN THE NEONATAL PERIOD | |
MX2015009606A (en) | A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications. | |
RU2013125276A (en) | METHOD FOR PREDICTING PREECLAMPSIA IN PREGNANT WOMEN WITH PLACENTAL INSUFFICIENCY | |
MX2016005973A (en) | Glycoprotein hormone long-acting superagonists. | |
RU2014149310A (en) | METHOD FOR PREVENTION AND TREATMENT OF BEAUTIFUL BREEDING OF BEES | |
RU2012118140A (en) | METHOD FOR INDIVIDUAL PURPOSE OF SYSTEM PULSE THERAPY BY Glucocorticosteroids to PATIENTS WITH ENDOCRINE OPHTHALMopathy | |
RU2010137386A (en) | METHOD FOR FORECASTING DISEASE RECIDENCE | |
UA103559U (en) | Method for forecasting zinc deficiency in patients in intensive care | |
UA83553U (en) | Method for prediction of development of recurrent course of pyelonephritis | |
RU2012118886A (en) | METHOD OF TASKING INDIVIDUAL RUNNING LOADS FOR ENDURANCE DEVELOPMENT | |
RU2012138516A (en) | METHOD FOR PREDICTING A RISK OF DEVELOPMENT OF A SEVERE NERVOUS SYSTEM IN NEWBORN CHILDREN WITH VARIOUS PERIODS OF GESTATION IN THE NEONATAL PERIOD | |
RU2013132754A (en) | METHOD FOR FORECASTING DEVELOPMENT OF ACQUIRED MYOPERITY IN SCHOOLCHILDREN | |
UA112100U (en) | METHOD OF ASSIGNMENT OF PATIENTS WITH STABLE ISCHEMIC HEART DISEASE TO THE RISK GROUP OF DEVELOPMENT OF CARDIOVASCULAR DEATH | |
EA201992633A1 (en) | TREATMENT OF POSITIVE ON LAG-3 TUMORS | |
RU2014119325A (en) | A method for predicting the risk of chronic atrial fibrillation in patients with cardiovascular disease |